πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

218 results for β€œMerck” Clear

  1. HYDROCORTISONE, PREDNISONE ACETATE, ENZALUTAMIDE, DEXAMETHASONE ACETATE, PREDNISONE, Opevesostat, ABIRATERONE ACETATE, DEXAMETHASONE, HYDROCORTISONE , HYDROCORTISONE, FLUDROCORTISONE, ABIRATERONE ACETATE, PREDNISOLONE, HYDROCORTISONE, FLUDROCORTISONE ACETATE

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer

    phase 3 small molecule active

    1 trial

  2. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ENFORTUMAB VEDOTIN

    Merck Sharp and Dohme

    Muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  3. KEYTRUDA 25 mg/mL concentrate for solution for infusion, GEMCITABINE , ENFORTUMAB VEDOTIN , CISPLATIN

    Merck Sharp and Dohme

    Muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  4. KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-3475A

    Merck Sharp and Dohme

    Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS β‰₯50%

    phase 3 small molecule active

    1 trial

  5. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Placebo to MK-1084 25 MG, MK-1084, Placebo to MK-1084 50 mg, MK-1084

    Merck Sharp and Dohme

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  6. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Placebo to MK-3475, CISPLATIN , GEMCITABINE

    Merck Sharp and Dohme

    Biliary Tract Carcinoma

    phase 3 small molecule active

    1 trial

  7. KEYTRUDA 25 mg/mL concentrate for solution for infusion, SUNITINIB , AXITINIB

    Merck Sharp and Dohme

    Metastatic renal cell carcinoma

    phase 3 small molecule active

    1 trial

  8. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Saline Solution

    Merck Sharp and Dohme

    Stage III melanoma (AJCC R0) with histologically confirmed cutaneous melanoma metastatic to lymph node, classified as (AJCC, 2010): Stage IIIA with metastasis > 1 mm; any Stage IIIB or IIIC (no in-transit metastases)

    phase 3 small molecule active

    1 trial

  9. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Sodium chloride

    Merck Sharp and Dohme

    Stage IB (T β‰₯ 4 cm), II and IIIA NSCLC

    phase 3 small molecule active

    1 trial

  10. Lenvatinib, Belzutifan, Lenvatinib

    Merck Sharp and Dohme

    Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dMMR colorectal cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, non-MSIH/dMMR endometrial cancer, esophageal squamous cell carcinoma, Advanced Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, von Hippel-Lindau (VHL)Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor, Advanced Solid Tumors With HIF-2Ξ± related Genetic Alterations

    phase 3 small molecule active

    1 trial

  11. MEDROXYPROGESTERONE , Opevesostat, EXEMESTANE , LETROZOLE , MEGESTROL , FLUDROCORTISONE , TAMOXIFEN , FULVESTRANT , HYDROCORTISONE , DEXAMETHASONE

    Merck Sharp and Dohme

    Breast cancer, Ovarian cancer, Endometrial cancer

    phase 3 small molecule active

    1 trial

  12. MK-0616

    Merck Sharp and Dohme

    Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  13. MK-0616, Placebo to MK-0616

    Merck Sharp and Dohme

    ​Heterozygous Familial Hypercholesterolemia​ in pediatric patients

    phase 3 small molecule active

    1 trial

  14. MK-0616, Placebo to MK-0616 - Tablet

    Merck Sharp and Dohme

    ASCVD - Atherosclerotic Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  15. MK-1022, CAPECITABINE , PACLITAXEL , TRASTUZUMAB DERUXTECAN , PACLITAXEL ALBUMIN-BOUND, DOXORUBICIN , DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL

    Merck Sharp and Dohme

    Hormone receptor positive breast cancer

    phase 3 small molecule active

    1 trial

  16. MK-1084, MK-3475A, CARBOPLATIN , PEMETREXED , MK-1084, CISPLATIN , Placebo for MK-1084

    Merck Sharp and Dohme

    Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated NSCLC

    phase 3 small molecule active

    1 trial

  17. MK-2870, CAPECITABINE , CYCLOPHOSPHAMIDE , PACLITAXEL , DEXAMETHASONE , DOXORUBICIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, EPIRUBICIN , CARBOPLATIN

    Merck Sharp and Dohme

    Breast Cancer: triple negative breast cancer (TNBC) and hormone receptor (HR)-low positive/HER2 negative breast cancer

    phase 3 small molecule active

    1 trial

  18. MK-2870, GEMCITABINE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , -, PACLITAXEL ALBUMIN-BOUND, PACLITAXEL

    Merck Sharp and Dohme

    Locally recurrent unresectable or metastatic TNBC with tumors expressing PD-L1 at the cut-off of CPS <10

    phase 3 small molecule active

    1 trial

  19. MK-2870, PACLITAXEL , -, PARACETAMOL , -, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , CISPLATIN , GEMCITABINE , -, PEMETREXED

    Merck Sharp and Dohme

    Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB (with nodal involvement [N2])

    phase 3 small molecule active

    1 trial

  20. MK-2870, PACLITAXEL ALBUMIN-BOUND, -, PACLITAXEL , -, -, DOXORUBICIN , PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTICS

    Merck Sharp and Dohme

    Endometrial cancer

    phase 3 small molecule active

    1 trial

  21. MK-2870, PARACETAMOL , TOPOTECAN , -, TISOTUMAB VEDOTIN, IRINOTECAN , PEMETREXED , -, -, GEMCITABINE , MK-2870, VINORELBINE

    Merck Sharp and Dohme

    Recurrent or metastatic cervical cancer that has progressed on or after treatment with platinum-doublet systemic chemotherapy and anti-PD-L1/anti-PD-1 therapy.

    phase 3 small molecule active

    1 trial

  22. MK-3475A, PEMETREXED , MK-1084, MK-1084, CISPLATIN , CARBOPLATIN , MK-1084, MK-1084

    Merck Sharp and Dohme

    Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC

    phase 3 small molecule active

    1 trial

  23. MK-3543, HYDROXYCARBAMIDE , Placebo for hydroxycarbamide, MK-3543, MK-3543, MK-3543, Placebo for Bomedemstat

    Merck Sharp and Dohme

    Essential thrombocythemia

    phase 3 small molecule active

    1 trial

  24. MK-3543, MK-3543, MK-3543, MK-3543

    Merck Sharp and Dohme

    Myeloproliferative Neoplasms (Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources